Allon Completes Dosing for AL-108 Phase Ib Clinical Trial

Allon Completes Dosing for AL-108 Phase Ib Clinical Trial: "Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that dosing has been completed in a Phase Ib human clinical trial evaluating the Company's product AL-108 as a treatment for Alzheimer's disease."